The vaccine is the second to receive emergency approval from the organization, but it is the first that can be administered to children from one year of age onwards.
The (WHO) took a significant step in the fight against it by approving the first vaccine intended for emergency use in children. The decision was announced after a meeting held last Tuesday (19), marking a crucial step forward in the fight against the disease. The vaccine, known as LC16 M8, is the second to receive emergency approval from the WHO for Mpox, but stands out for being the first that can be administered to children from one year of age.
Furthermore, it is recommended for people considered at high risk, although there are contraindications for pregnant women and immunosuppressed individuals. After WHO approval, the immunizer must be approved by the regulatory agencies in each country. This decision follows the declaration of international emergency for Mpox made by the WHO in August. Since then, the first vaccine against the disease has been approved, and now, the second, which also offers protection for children.
Mpox has been a growing concern globally, with cases reported in at least 80 countries by 2024, according to WHO data. Among these countries, 19 are African nations, with the Democratic Republic of Congo standing out for the highest number of cases and deaths. In , the situation is equally alarming, with more than 1,500 cases reported as of last week.
Published by Luisa Cardoso
